

Parunya Chaiyawat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7203760/publications.pdf>

Version: 2024-02-01

28
papers

462
citations

759233

12
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

658
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. <i>Proteomics</i> , 2013, 13, 2088-2099.	2.2	75
2	Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer. <i>Oncology Reports</i> , 2013, 30, 2929-2936.	2.6	54
3	Aberrant O-GlcNAcylated Proteins: New Perspectives in Breast and Colorectal Cancer. <i>Frontiers in Endocrinology</i> , 2014, 5, 193.	3.5	34
4	Alteration of O-GlcNAcylation affects serine phosphorylation and regulates gene expression and activity of pyruvate kinase M2 in colorectal cancer cells. <i>Oncology Reports</i> , 2015, 34, 1933-1942.	2.6	29
5	Overexpression of KH-type splicing regulatory protein regulates proliferation, migration, and implantation ability of osteosarcoma. <i>International Journal of Oncology</i> , 2016, 49, 903-912.	3.3	26
6	Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications. <i>Modern Pathology</i> , 2018, 31, 264-274.	5.5	26
7	Prognostic score for life expectancy evaluation of lung cancer patients after bone metastasis. <i>Journal of Bone Oncology</i> , 2018, 10, 1-5.	2.4	24
8	Exploring targeted therapy of osteosarcoma using proteomics data. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 565-577.	2.0	22
9	Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent. <i>European Journal of Pharmacology</i> , 2020, 887, 173580.	3.5	22
10	Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment. <i>International Journal of Cancer</i> , 2020, 146, 3397-3409.	5.1	20
11	Protein profiling of osteosarcoma tissue and soft callus unveils activation of the unfolded protein response pathway. <i>International Journal of Oncology</i> , 2019, 54, 1704-1718.	3.3	14
12	Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial. <i>BMC Cancer</i> , 2020, 20, 268.	2.6	14
13	Oncogenic roles of serine-threonine kinase receptor-associated protein (STRAP) in osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1039-1047.	2.3	12
14	Elevated O-GlcNAcylation of Extracellular Vesicle Proteins Derived from Metastatic Colorectal Cancer Cells. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 387-98.	2.0	12
15	Size distribution of cell-free DNA in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103455.	4.4	11
16	Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma. <i>Journal of Bone Oncology</i> , 2019, 16, 100233.	2.4	10
17	Surgical outcomes of extracorporeal irradiation and re-implantation in extremities for high grade osteosarcoma: A retrospective cohort study and a systematic review of the literature. <i>Journal of Bone Oncology</i> , 2019, 14, 100210.	2.4	10
18	Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma. <i>Cancers</i> , 2021, 13, 4214.	3.7	10

#	ARTICLE	IF	CITATIONS
19	Osteosarcoma-Specific Genes as a Diagnostic Tool and Clinical Predictor of Tumor Progression. <i>Biology</i> , 2022, 11, 698.	2.8	9
20	Safety and efficacy of intralesional steroid injection for aggressive fibromatosis. <i>World Journal of Surgical Oncology</i> , 2017, 15, 195.	1.9	5
21	Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 25, 100321.	2.4	5
22	Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma. <i>Translational Oncology</i> , 2017, 10, 846-853.	3.7	4
23	Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer. <i>Glycoconjugate Journal</i> , 2021, 38, 55-65.	2.7	4
24	IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma. <i>Scientific Reports</i> , 2021, 11, 10887.	3.3	4
25	Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification. <i>Oncology Reports</i> , 2018, 40, 2193-2205.	2.6	3
26	In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1165-1176.	2.3	1
27	Relationship Between O-GlcNAcase Expression and Prognosis of Patients With Osteosarcoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, e1-e10.	1.2	1
28	An analysis of the incidence and survival rates of bone sarcoma patients in thailand: reports from population-based cancer registries 2001â€“2015. <i>Cancer Epidemiology</i> , 2022, 76, 102056.	1.9	1